NCT04344769Recruiting
Characterization of the Nrf2 Response in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Source: ClinicalTrials.gov · Last updated 16 Jan 2026
Brief summary (registry, in English)
The purpose of this study is to characterize oxidative stress and the Nrf2 antioxidant response in early stages of Autosomal Dominant Polycystic Kidney Disease (ADPKD), while identifying candidate biomarkers.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 40 (estimated)
- First submitted
- 10 Apr 2020
- Start date
- 4 Oct 2019
- Primary completion date
- Dec 2026
- Lead sponsor
- Mayo Clinic
- Diseases
- Polycystic kidney disease
- NCT number
- NCT04344769
What you commit to
- Study type: Observational
- Planned participants: 40
- From 4 Oct 2019 to the primary completion date, Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Concomitant systemic disease in the kidney (e.g. lupus, hepatitis B or C, amyloidosis)
- Abnormal urinalysis suggestive of concomitant glomerular disease.
- Previous personal or family history of kidney disease.
- Concomitant systemic disease in the kidney (e.g. lupus, hepatitis B or C, amyloidosis)
Other illness
- Abnormal urinalysis suggestive glomerular disease.
Lab values
- Diabetes mellitus (fasting glucose \> 126 mg/dL or treatment with insulin or oral hypoglycemics).
- Diabetes mellitus (fasting glucose \> 126 mg/dL or treatment with insulin or oral hypoglycemics).
Other
- Class 2 according to our imaging classification
- Predicted urine protein excretion in urinalysis \>1 g/24 hrs
- Subjects having contraindications to, or interference with MRI assessments. \[For example: ferromagnetic metal prostheses, aneurysm clips, severe claustrophobia, large abdominal/back tattoos, etc\].
- Female subjects that are pregnant
- Presence of proteinuria
- Subjects having contraindications to, or interference with MRI assessments. \[For example: ferromagnetic metal prostheses, aneurysm clips, severe claustrophobia, large abdominal/back tattoos, etc\]
- Female subjects that are pregnant
Who the study is looking for
- ADPKD (based on Ravine et al. criteria)
- Class 1 B-E according to our imaging classification
- Male and female subjects 18 - 30 years of age, inclusive
- Estimated GFR\> 60 mL/min/m2 (CKD-EPI equation)
- Ability to provide written, informed consent.
- Male and female subjects 18 - 30 years of age, inclusive
- Estimated GFR\> 60 mL/min/m2 (CKD-EPI equation)
- Ability to provide written, informed consent.
Age in the registry: 18 years to 30 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Mayo Clinic in Rochester Coordinator of this site? Confirm its status | Rochester | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.